CYP24A1 is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma
Overview
Authors
Affiliations
Purpose: The active form of vitamin D, 1α,25-dihydroxyvitamin D(3) (1,25-D(3)), exerts antiproliferative effects in cancers, including lung adenocarcinoma (AC). CYP24A1 is overexpressed in many cancers and encodes the enzyme that catabolizes 1,25-D(3). The purpose of our study was to assess CYP24A1 as a prognostic marker and to study its relevance to antiproliferative activity of 1,25-D(3) in lung AC cells.
Experimental Design: Tumors and corresponding normal specimens from 86 patients with lung AC (stages I-III) were available. Affymetrix array data and subsequent confirmation by quantitative real time-PCR were used to determine CYP24A1 mRNA expression. A subsequent validation set of 101 lung AC was used to confirm CYP24A1 mRNA expression and its associations with clinical variables. The antiproliferative effects of 1,25-D(3) were examined using lung cancer cell lines with high as well as low expression of CYP24A1 mRNA.
Results: CYP24A1 mRNA was elevated 8- to 50-fold in lung AC (compared to normal nonneoplastic lung) and significantly higher in poorly differentiated cancers. At 5 years of follow-up, the probability of survival was 42% (high CYP24A1, n = 29) versus 81% (low CYP24A1, n = 57) (P = 0.007). The validation set of 101 tumors showed that CYP24A1 was independently prognostic of survival (multivariate Cox model adjusted for age, gender, and stage, P = 0.001). A549 cells (high CYP24A1) were more resistant to antiproliferative effects of 1,25-D(3) compared with SKLU-1 cells (low CYP24A1).
Conclusions: CYP24A1 overexpression is associated with poorer survival in lung AC. This may relate to abrogation of antiproliferative effects of 1,25-D(3) in high CYP24A1 expressing lung AC.
DNA Methylation in Colorectal Cancer as Potential Prognostic and Predictive Markers.
Zhou R, Li L, Ou Q, Wang Y, Fang Y, Zhang C Biomolecules. 2025; 15(1).
PMID: 39858498 PMC: 11763947. DOI: 10.3390/biom15010104.
Xu M, Liu Y, Kuang X, Pu Y, Jiang Y, Zhao X iScience. 2024; 27(7):110286.
PMID: 39055952 PMC: 11269300. DOI: 10.1016/j.isci.2024.110286.
Perez-Duran C, Marquez-Pete N, Galvez-Navas J, Cura Y, Rojo-Tolosa S, Pineda-Lancheros L Cancers (Basel). 2023; 15(16).
PMID: 37627104 PMC: 10452893. DOI: 10.3390/cancers15164077.
Li H, Wang W, Huang Z, Zhang P, Liu L, Sha X J Thorac Dis. 2023; 15(6):3054-3068.
PMID: 37426132 PMC: 10323588. DOI: 10.21037/jtd-22-1522.
Pineda-Lancheros L, Galvez-Navas J, Rojo-Tolosa S, Membrive-Jimenez C, Valverde-Merino M, Martinez-Martinez F Nutrients. 2023; 15(6).
PMID: 36986255 PMC: 10057500. DOI: 10.3390/nu15061525.